China NMPA Drug Inspection - Jilin Province Cross-Sea Biochemical Pharmaceutical Manufacturing Co., Ltd. - Anti-osteoproliferative pills
China NMPA drug inspection for Jilin Province Cross-Sea Biochemical Pharmaceutical Manufacturing Co., Ltd. published April 25, 2017. Drug: Anti-osteoproliferative pills. The Shaanxi Provincial Food and Drug Administration issued a Drug Quality Announcement on April 25, 2017, detailing find
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Jilin Province Cross-Sea Biochemical Pharmaceutical Manufacturing Co., Ltd. published April 25, 2017. Drug: Anti-osteoproliferative pills. The Shaanxi Provincial Food and Drug Administration issued a Drug Quality Announcement on April 25, 2017, detailing find
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox